CoChat

Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging

Open access
Lui, James K., for the AIBL Research Group, Laws, Simon M., Li, Qiao-Xin, Villemagne, Victor L., Ames, David, Brown, Belinda, Bush, Ashley I., De Ruyck, Karl, Dromey, Jasmin, Ellis, Kathryn A., Faux, Noel G., Foster, Jonathan, Fowler, Christopher, Gupta, Veer, Hudson, Peter, Laughton, Katrina, Masters, Colin L., Pertile, Kelly, Rembach, Alan, Rimajova, Mira, Rodrigues, Mark, Rowe, Christopher C., Rumble, Rebecca, Szoeke, Cassandra, Taddei, Kevin, Taddei, Tania, Trounson, Brett, Ward, Vanessa, Martins, Ralph N. · 2010 · Journal of Alzheimer's Disease
Cited by 134

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Amyloid-beta (Abeta) plays a central role in the pathogenesis of Alzheimer's disease (AD) and has been postulated as a potential biomarker for AD. However, there is a lack of consensus as to its suitability as an AD biomarker. The objective of this study was to determine the significance of plasma Abeta as an AD biomarker and its relationship with Abeta load and to determine the effect of different assay methods on the interpretation of Abeta levels. Plasma Abeta1-40, Abeta1-42, and N-terminal cleaved fragments were measured using both a commercial multiplex assay and a well-documented ELISA in 1032 individuals drawn from the well-characterized Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Further, Abeta levels were compared to Abeta load derived from positron-emission tomography (PET) with the Pittsburgh compound B (PiB). Lower Abeta1-42 and Abeta1-42/1-40 ratio were observed in patients with AD and inversely correlated with PiB-PET derived Abeta load. However, assay methodology significantly impacted the interpretation of data. The cross-sectional analysis of plasma Abeta isoforms suggests that they may not be sufficient per se to diagnose AD. The value of their measurement in prognosis and monitoring of AD interventions needs further study, in addition to future longitudinal comparisons together with other predictors, which will determine whether plasma Abeta has diagnostic value in a panel of biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-2010-090249

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 134

Metadata

Authors
Lui, J. K., for the AIBL Research Group, Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., Bush, A. I., De Ruyck, K., Dromey, J., Ellis, K. A., Faux, N. G., Foster, J., Fowler, C., Gupta, V., Hudson, P., Laughton, K., Masters, C. L., Pertile, K., Rembach, A., Rimajova, M., Rodrigues, M., Rowe, C. C., Rumble, R., Szoeke, C., Taddei, K., Taddei, T., Trounson, B., Ward, V., & Martins, R. N.
Venue
Journal of Alzheimer's Disease
Published
2010-06-13
Volume
20
Issue
4
Pages
1233-1242
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1484920908
Cited by
134
References
17
FWCI
7.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. https://app.cochat.ai/papers/10.3233/jad-2010-090249
The paper
Lui, J. K., for the AIBL Research Group, Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., Bush, A. I., De Ruyck, K., Dromey, J., Ellis, K. A., Faux, N. G., Foster, J., Fowler, C., Gupta, V., Hudson, P., Laughton, K., Masters, C. L., Pertile, K., . . . Martins, R. N. (2010). Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-090249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.